Abstract
Secukinumab for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Post Hoc Analyses of Efficacy Endpoints, Draining Tunnels, Skin Pain, and Work Productivity
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have